Physicians concerned with the diagnosis, management, and care of patients with phenylalaninaemia,* are acutely aware of their inability to differentiate all patients who require restrictive dietary therapy from those who do not. This is due primarily to the bias introduced when phenylketonuria (PKU) was first discovered and the sequence of the subsequent screening programmes developed to recognize this disorder during the neonatal period.
Time and experience have shown that some of the patients identified as PKU in early blood screening statistical reports were in all probability examples of a variety of atypical PKU patients (Blaskovics and Nelson, 1971; Levy, 1973) . The term in vogue at the present time for all forms of atypical phenylalaninaemic patients is 'variants'. It is extremely important to recognize these variant patients because their prognosis without treatment is different from classical PKU. Most variant patients have been treated unnecessarily in the past, and many still are because of the prevailing attitudes before the use of blood screening programmes that all raised blood phenylalanine (phe) levels inexorably led to mental retardation. Since there was no previous experience for defining PKU on the basis of abnormal blood phe levels in normal newborn populations, different blood phe levels were arbitrarily adopted by clinicians and investigators throughout the world and equated with PKU. Up to the present time, reports still describe patients as having 'classical PKU' or as being 'hyperphenylalaninaemic' (in the present context equivalent to variant) without describing how the diagnosis was made, and even less, how it was confirmed. Most investigators still use a fixed blood phe level as the diagnostic criterion for PKU; for example, 15 or 20 mg/100 ml. Yet, it is eminently clear from individual case reports (Justice, O'Flynn, and Hsia, 1967;  Blaskovics, 1971 Blaskovics, , 1973 Blaskovics and Shaw, 1971) and from the findings of the Collaborative Study of the Treatment for PKU (Koch et al., 1973) that an arbitrary and fixed serum phe level cannot predict permanence nor the degree of phe intolerance in all patients and, therefore, cannot predict PKU. This paper describes, therefore, a method developed to aid in differentiating various forms of phenylalaninaemia. A classification also is suggested which is based on longitudinal observations and tolerance tests of approximately 25 patients with PKU and 35 patients with other phenylalaninaemic conditions. The subjects ranged from infancy (3 weeks) to adulthood (35 years). All for phe and metabolites in initial patient studies, but when it was confirmed that urinary metabolite levels generally reflected and were proportional to serum phe levels, as has been described by Armstrong and Low (1957) , further urinary studies were discontinued. Furthermore, since some variant patients excrete PPyA (phenylpyruvic acid), which has been assumed to be the hallmark of PKU, this parameter, though helpful, was not judged to be a meaningful discriminant for the absolute diagnosis of PKU. Urine from each patient was analysed to exclude the possibility of a phe-transaminase defect.
This method was developed primarily to evaluate and differentiate phenylalaninaemia in infants , but it can be used for older children and adults. For infants the challenge diet is easily provided as whole milk or diluted evaporated milk. Natural protein was chosen over supplementation of the basal diet with L-phe, or the use of L-phe alone because it avoided the problem of limiting amino acids, transport inhibitions, and also the side effects associated with the ingestion of large quantities of pure L-phe, such as nausea, emesis, ataxia, etc. In addition, since the trend in PKU therapy is to discontinue dietary treatment when the patients are less than 10 years of age, this challenge also predicts the probable maximum serum phe level that a patient could have when receiving a normal diet. Most normal diets, however, never contain the amount of phe and protein ingested during the challenge period, except during infancy. A diet of balanced proteins, e.g., milk, meat, cheese, eggs, etc., calculated to provide a phe intake of 180 mg/kg per day to older children and adults generally requires 2 to 5 times their normal protein consumption. As a precautionary measure, all patients were screened with tests to assess renal and hepatic function before the loading studies. No serious or persistent untoward responses to the challenges have been observed. When a patient showed signs of illness, the studies were immediately terminated until the patient was clinically well. Some patients were studied when they were ill to determine the effect of illness on responses to loading. This has been reported elsewhere (Blaskovics, 1971) . Challenges were begun with first moming feeds to minimize phe variations which might be related to circadian rhythms.
Almost all patients were studied at least twice, and most three or more times at different ages. Infants were usually studied at the time of initial referral, approximately 3 months later, and again at one year of age. Some patients had additional studies at yearly or 2-yearly intervals. Since all subjects were not studied during infancy, earlier levels of serum phe and of urinary metabolites for some patients were assumed on the basis of studies of other patients who were evaluated both during infancy and again at later ages. The clinicalbiochemical attributes of each type of phenylalaninaemia are suggested principally from these patient studies, but some types necessarily are based on case reports, which are referenced, unless personally observed.
Phenylalaninaemias
Type I. Of all the phenylalaninaemias (Table) , this group has the highest serum phe levels at any time in life, e.g., greater than 50 mg/100 ml. The urinary metabolites are quantitatively the most markedly abnormal. A typical challenge response during infancy can be seen in Fig. 1 (Barranger, et al., 1972; Kaufmann and Fisher, 1970) suggest that phenylalanine hydroxylase activity may be the sum of 2 or 3 isoenzymes.
tThe metabolites most frequently cited in association with PKU are phenylpyruvic acid, PPyA; ortho-hydroxyphenylacetic acid, oHPAA; and phenylacetic acid, PAA (cause of the odour). However, many laboratories can routinely determine phenylacetylglutamine, phenyl-lactic acid, mandelic acid, n-acetyl phenylalanine, m-hydroxyphenylacetic acid, and other metabolites. (Blaskovics, 1974) , were recognized in this manner. The similarity in responses to the standardized challenge by these 5 patients, and other patients studied in this clinic, strongly suggests that type III patients represent a distinct genetic population. The enzyme defect appears to be different from that of types I and II, regardless of whether or not it affects the same enzyme as in types I or II phenylalaninaemia (true PKU). Type III phenylalaninaemia is considered to be a variant disorder because of its generally benign nature. One patient who appears to have a type III response is retarded. It is conceivable that his retardation is related to the raised phe levels, but an older untreated sib with less tolerance to phe, but who has a precisely similar response to the challenge diet (Fig. 5) , has superior intelligence (IQ 128) and is functionally normal in all respects.
Another form of phenylalaninaemia which has been included under the umbrella of 'hyperphenylalaninaemia' and is usually presented as one population is classified in the present studies as two subpopulations, designated types IV and V. Patients in both groups show normal intelligence without dietary restriction and EEGs, and other clinical parameters are almost always normal.
Type IV. In this group, serum phe levels on unrestricted dietary intakes during the early weeks of life range between 15 and 20 mg/100 ml. Urine may show metabolites associated with PKU, but intermittently, uncommonly, and at very low levels in proportion to the low serum phe levels. Serum phe levels during adulthood are normal or just above normal, e.g. 4 to 6 mg/100 ml. These patients are relatively easy to recognize in infancy because of their low serum phe levels while receiving normal or regular diets. A sustained phe intake of approximately 180 mg/kg per day often will cause serum phe levels to increase initially, then to decrease suddenly and stabilize between 12 and 20 mg/lX)mI mg/100 ml, a response similar to type III patients but at lower levels (Fig. 6 ). This response also suggests induction of enzyme activity. The PKU odour due to phenylacetic acid is inifrequently present.
Type V. Type V phenylalaninaemia is the one most easily recognized during infancy. Serum phe levels on regular diets are almost consistently less than 10 mg/100 ml in the first year of life, except during illnesses, when they may rise as high as 20 mg/100 ml and metabolites typical of PKU may be found in urine. Overloading with phe, e.g. intakes greater than 225 to 250 mg/kg per day, usually does not cause a phenylketonuric chemical response in these infants (Fig. 7a and b) . These patients develop normally without dietary restrictions and serum phe levels decrease early into a normal range. The eventually normal phe level is probably a consequence of the decreased protein and phe intakes per unit of body weight, which naturally occurs with increasing age. However, an increased phe intake can show the minimal impairment in phe metabolism even at older ages ( Fig. 8 and 9 ). These seemingly normal subjects may be the adults who with L-phe challenges have abnormal phe responses and are sometimes called, The response typical of a normal control patient to a high phe and protein intake is shown in Fig. 10 Type VII. Phenylalaninaemia associated with ctransient tyrosinaemia of the neonate' has no proven morbidity, but it is important because it is the most frequent cause of raised serum phe. The diagnosis is made by determining a raised serum tyrosine level (5 to 50 mg/100 ml) in conjunction with a raised serum phe (6 to 20 mg/100 ml). Both abnormal amino acid levels usually normalize within a week when protein intake is reduced. This reversible condition is noted most frequently in premature infants and in term infants receiving very high protein intakes. Though vitamin C has been shown to be a co-factor for the para-hydroxyphenylpyruvic acid oxidase enzyme which is inhibited by the accumulation of substrates present in transient tyrosinaemia, there is good evidence that the practice of supplementing these patients with excess vitamin C is of little value in decreasing the tyrosinaemia (Raine et al., 1972) . Type VIII. The phenylalaninaemia which is seen with tyrosinosis is clinically of no consequence. Serum tyrosine is only slightly raised (3 to 10 mg/100 ml), and the serum phe level is usually just above the minimum needed for a positive Guthrie test (4 to 6 mg/100 ml). The diagnosis is made on clinical grounds, e.g. hepatomegaly, failure to thrive, rickets, and the finding of generalized aminoaciduria of the pattern usually associated with a renal deToni-Fanconi Syndrome.
Other nonspecific causes of phenylalaninaemia. There are other causes of raised serum phe not included in this scheme. The infant born to a mother with PKU is one example (Forbes et al., 1966) . Another example is galactosaemia, which can cause a transient and mildly raised serum phe level due probably to the liver damage of galactosaemia (R. Guthrie, personal communication, 1972) .
Discussion
The first newborn PKU screening reports in Massachusetts suggested an incidence of 1:7000, whereas a more recent report from there indicated a probable PKU incidence of 1:16,000 (Levy, 1973) . These discrepancies are due to the fact that the earlier newborn screening reports included patients with phenylalaninaemia due to causes other than true PKU.
The lack of unanimity about the definition of PKU makes it virtually impossible to arrive at true incidence figures. For example, in some centres (Bickel, 1968; McBean, 1970) phe levels of 8 to 10 mg/100 ml are considered consistent with mild PKU and treatment is initiated. Other centres (Berry, Sutherland, and Umbarger, 1966 ) consider a phe level of 15 or 20 mg/100 ml (J. Berman, personal communication, 1973) as diagnostic for PKU and as the criterion for treatment versus nontreatment. A definition of PKU based only on random or isolated blood phe levels is arbitrary and will be influenced by the experience and prejudices of the individual investigator.
The incidence of phenylalaninaemia types III, IV, and V cannot yet be given; screening reports suggest that approximately 1/3 to 1/2 of all patients with phenylalaninaemia are in these clinically benign groups (Blaskovics and Nelson, 1971; Levy, 1973 (Dancis, 1967) . Eventually, no doubt, diagnoses in the phenylalaninaemias will be made on the basis of total enzyme activity and/or enzyme components or isoenzymes. 
